Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)

NCT03730012 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.

NCT NCT03730012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03730012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)
Lead sponsor
Astellas Pharma Global Development, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
June 19, 2019
Completion date
June 15, 2021
Enrollment
11 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), acute myeloid leukemia with fms-like tyrosine kinase (flt3) mutation